Riskpilot← Back to searchSign inGet full accessAkleja Kvinnoklinik AB
ABActiveOrg 5592086762Västerlånggatan 20Medical specialists activities · NACE 8622Est. 201934 employees
Revenue 2025
SEK 60,3M
+18% vs 2024
EBITDA margin
21.0%
+30% vs 2024
Equity ratio
47.9%
Financial strength
Net profit 2025
SEK 8,9M
+25% vs 2024
| Revenue | SEK 60,3M | +18% |
| EBITDA | SEK 12,7M | +30% |
| Net profit | SEK 8,9M | +25% |
| Total assets | SEK 19,3M | +26% |
| Equity | SEK 9,2M | +26% |
| Employees | 34 | — |
Legal name
Akleja Kvinnoklinik AB
Org number
5592086762
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
11 juni 2019
Share capital
SEK 200 100
Employees
34 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Läkarpraktik inom gynekologi och obstetrik. Undervisning inom obstetik och gynekologi och utvecklingsarbete inom sjukvårds- verksamhet, företrädesvis obstetrik och gynekologi.
Address
Västerlånggatan 20
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 5 930 | 10 979 | 34 667 | 51 174 | 60 268 |
| Staff expenses | — | −4 006 | −12 513 | — | −24 806 |
| EBITDA | 619 | 1 033 | 10 476 | 9 713 | 12 651 |
| Depreciation & amort. | −30 | −25 | −162 | −414 | −550 |
| EBIT | 589 | 1 008 | 10 314 | 9 299 | 12 101 |
| Net financials | — | −0 | 15 | −7 | −16 |
| Profit before tax | 589 | 1 008 | 7 598 | 9 013 | 11 359 |
| Tax | −132 | −229 | −1 607 | −1 897 | −2 431 |
| Net profit | 457 | 779 | 5 990 | 7 116 | 8 928 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 748 | 2 669 | 13 423 | 15 297 | 19 313 |
| Equity | 660 | 983 | 6 223 | 7 317 | 9 244 |
| Long-term debt | 0 | — | — | 0 | — |
| Short-term debt | 1 088 | 1 687 | 4 469 | 4 970 | 7 085 |
| Total debt | 1 088 | 1 687 | 4 469 | 4 970 | 7 085 |
EBITDA margin
21.0%
This company
15.8%
Market median
+33% vs market
20212025
Equity ratio
47.9%
This company
38.2%
Market median
+25% vs market
20212025
Return on equity
96.6%
This company
18.4%
Market median
+425% vs market
20212025
Net profit margin
14.8%
This company
8.1%
Market median
+83% vs market
20212025
Asset turnover
3.12×
This company
1.12×
Market median
+179% vs market
20212025
Debt / equity
1.09×
This company
0.62×
Market median
-76% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
PB Chief Auditor | Chief Auditor | 2021 |
PP Chief Executive Officer | Chief Executive Officer | 2021 |
MN Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Akleja Kvinnoklinik Väst AB
Akleja Kvinnoklinik AB Board members of Akleja Kvinnoklinik AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Bo Weine Karlsson | Chief Auditor | 0 companies |
| Pantea Piravogi Camling | Chief Executive Officer | 0 companies |
| Mahsa Nordqvist | Deputy Chief Executive Officer | 0 companies |
| Jennifer Sandra Campbell | Chairman | 0 companies |